SciELO - Scientific Electronic Library Online

vol.14 número2Voriconazol e caspofungina versus anfotericina B para tratamento de aspergilose em pacientes com neoplasias malignas hematológicas, neutropenia febril ou submetidos a transplante de órgãosTratamento de adultos com hepatite viral C crônica de genótipo 1 com inibidores de protease (boceprevir e ou telaprevir) índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

BIS. Boletim do Instituto de Saúde (Impresso)

versão impressa ISSN 1518-1812


TOMA, Tereza Setsuko; VENANCIO, Sonia Isoyama; MARTINS, Patrícia Nieri  e  SATO, Helena Keico. Prophylactic use of palivizumab in the prevention of respiratory syncytial virus infection in high-risk children. BIS, Bol. Inst. Saúde (Impr.) [online]. 2013, vol.14, n.2, pp. 213-220. ISSN 1518-1812.

The palivizumab, a humanized IgG1 monoclonal antibody, was registered in the National Health Surveillance Agency - ANVISA in 1999. Usually, 5 doses monthly / child beginning before the seasonality of RSV are  sufficient. Objective: to determine whether prophylaxis with palivizumab reduces hospitalization and mortality from RSV infection in high-risk children. Methods: A search looking for reports on Health Technology Assessment, systematic reviews and randomized clinical trials was carried out in scientific literature databases. A number of the Boletim da Rede Brasileira de Avaliação de Tecnologias em Saúde, published in 2011, contained a technical report on palivizumab and was taken as a reference. An update task was carried out from three systematic reviews presented in this bulletin. Results: The results of the reviews were similar, showing that prophylaxis with palivizumab was effective in reducing the number of hospitalizations. The results regarding the reduction of mortality are still controversial. Conclusion: The palivizumab is dispensed by the Health Secretariat of São Paulo State since 2007. The Ministry of Health decided in 2012 by the incorporation of palivizumab for premature infants with gestational age less than or equal to 32 weeks and children up to 2 years with chronic lung disease or congenital heart disease.

Palavras-chave : Palivizumab; Respiratory Syncytial Virus; Hospitalization.

        · resumo em Português     · texto em Português     · pdf em Português